New drugs for ovarian cancer.
Kaye
Stanley B
SB
Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D051017:Apoptosis Regulatory Proteins; D024682:BRCA2 Protein / Q000235:genetics; D000068258:Bevacizumab; D016190:Carboplatin / Q000627:therapeutic use; D017322:Clinical Trials, Phase II as Topic; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007191:Indazoles; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D017239:Paclitaxel / Q000627:therapeutic use; D011743:Pyrimidines; D016032:Randomized Controlled Trials as Topic; D013449:Sulfonamides; D044767:Ubiquitin-Protein Ligases / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; C118024:BLID protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; C516667:pazopanib; D016190:Carboplatin; C111164:BRAP protein, human; D044767:Ubiquitin-Protein Ligases; D017239:Paclitaxel